Ribera Salud CEO Resigns Amid Healthcare Quality Controversy

In a surprising turn of events, the Ribera Salud group announced tonight that its CEO, Pablo Gallart, has stepped down from his responsibilities related to the management of the Torrejón Hospital. This decision comes as the company embarks on a comprehensive audit in light of serious concerns regarding healthcare ethics and quality. The announcement follows the release of audios by EL PAÍS, in which Gallart is heard requesting an increase in waiting lists and excluding profitable processes, actions aimed at boosting financial benefits. Political reactions have intensified since the revelations. Following a meeting on September 25, where Gallart reportedly issued these controversial instructions, the Madrid government took swift action by summoning the hospital manager and pledging to implement necessary measures. Hours after these developments, Ribera Salud issued a statement underscoring its commitment to uphold ethical standards and provide quality care to patients. Spanish Prime Minister Pedro Sánchez voiced his concerns about the healthcare model advocated by the People's Party (PP), stating that the government will not permit illness to be monetized. He emphasized the unethical nature of leveraging health issues for profit. Mónica García, a political figure, launched a direct accusation against Isabel Díaz Ayuso, arguing that the latter prioritizes monetary gains over the wellbeing of lives, and hinted at potential legal actions against her. Additionally, the Madrid PSOE (Spanish Socialist Workers' Party) is contemplating judicial proceedings and has called for the Health Minister to appear before them to address these significant issues. In its defense, Ribera Salud reiterated its commitment to patient care, asserting that the company's primary focus, alongside that of its shareholder, Vivalto Santé, is the welfare of patients. The group stressed that the quality and rigor of care will remain uncompromised during this audit process. The unfolding situation continues to develop, as stakeholders await further updates and the ramifications of Gallart's resignation. Related Sources: • Source 1 • Source 2